Next-generation sequencing has revolutionized the field of medicine, with labs now able to dig through a patient’s entire genome to locate even the tiniest indicators of disease. And while this technology works remarkably fast compared to traditional diagnostic methods, it still requires quite a bit of dedicated time and effort to prepare DNA samples for processing.

Philips is looking to bolster its vascular franchise by absorbing Vesper Medical, maker of stents designed to open up blocked or narrowed veins in the legs.

How do cancer cells travel beyond the primary tumor, stay dormant for years and then suddenly wake up, causing cancer to recur? Researchers at Mount Sinai believe they may have found one answer—and that the discovery could offer new tools for predicting and preventing cancer relapses.

After making headlines this summer with first-in-human gene editing results, Intellia’s next therapy has officially landed in the clinic in patients with hereditary angioedema (HAE).

Next-generation sequencing has revolutionized the field of medicine, with labs now able to dig through a patient’s entire genome to locate even the tiniest indicators of disease. And while this technology works remarkably fast compared to traditional diagnostic methods, it still requires quite a bit of dedicated time and effort to prepare DNA samples for processing.

The FDA has begun outlining a potential approach for regulating a cutting-edge front emerging in healthcare: the 3D printing of medical implants or devices customized for each individual patient and manufactured on-site and on-demand within hospitals or doctor’s offices.

Most therapies for vascular diseases aim to treat risk factors like high blood pressure and cholesterol rather than repairing the damaged blood vessels. Now, a team of researchers at the University of Chicago has shown that a targeted nanomedicine may be able to address vascular lesions.

New follow-up data for Roche’s Tecentriq-tiragolumab combination therapy in certain lung cancer patients have analysts sighing in relief that the anti-TIGIT element appears to be pulling its weight, but two deaths in the combination arm hit the company’s shares Friday morning.

As it looks to one day move beyond COVID-19 vaccines and take its mRNA tech to other diseases, Moderna has established a new artificial intelligence training program for its employees in partnership with Carnegie Mellon University.

What happens when a three-month-old mouse racks up more than four miles a day exercising on his running wheel? His body produces a protein that tamps down inflammation in the brain. That discovery, from Stanford University’s School of Medicine, could inspire new treatments for Alzheimer’s and other neurodegenerative diseases, the researchers suggested.